Evaluation of the Safety and Efficacy of the FAAH Inhibitor URB597
Technical Report,01 May 2014,03 Oct 2015
New York University New York United States
Pagination or Media Count:
The award was to fund a 3-year program involving a phase I study to determine the safety, tolerability, and pharmacokinetics of orally administered URB597, the first potent and selective FAAH inhibitor, in healthy volunteers and a phase II study to determine the efficacy and safety of URB compared with placebo. Due to the Principal Investigators leaving the institution in March of 2015 the study was discontinued prior to the preclinical evaluations for pharmacokinetics and toxicology. The supply of URB597 that had been produced was shipped to the Uniformed Services University USU as instructed by USAMRMC, August 2015.